Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Decreased by HighTower Advisors LLC

HighTower Advisors LLC lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 115,790 shares of the biopharmaceutical company's stock after selling 9,251 shares during the quarter. HighTower Advisors LLC owned 0.09% of Alnylam Pharmaceuticals worth $31,931,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in ALNY. Eventide Asset Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 157.9% in the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company's stock valued at $61,698,000 after acquiring an additional 137,333 shares during the period. Los Angeles Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock valued at $37,684,000 after purchasing an additional 135,829 shares in the last quarter. AQR Capital Management LLC raised its position in Alnylam Pharmaceuticals by 92.5% in the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company's stock valued at $65,862,000 after purchasing an additional 130,482 shares during the period. Deerfield Management Company L.P. Series C acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $29,111,000. Finally, Avoro Capital Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 33.3% in the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company's stock worth $97,200,000 after buying an additional 100,000 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Royal Bank of Canada reissued an "outperform" rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price objective for the company from $198.00 to $370.00 in a research report on Friday, August 16th. TD Cowen lifted their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Bank of America increased their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a "buy" rating in a report on Monday, October 14th. Finally, HC Wainwright restated a "buy" rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $298.09.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company's stock, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the firm's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares of the company's stock, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,370 shares of company stock valued at $2,100,703. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $4.45 during midday trading on Friday, hitting $256.26. 574,956 shares of the company's stock were exchanged, compared to its average volume of 867,008. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The firm has a market cap of $33.05 billion, a P/E ratio of -96.11 and a beta of 0.32. The stock's 50 day moving average price is $269.49 and its 200-day moving average price is $243.89. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period last year, the firm posted $1.15 earnings per share. The business's quarterly revenue was down 33.3% on a year-over-year basis. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.